Jacqueline Shea, Ph.D.

Dr. Jacqueline Shea has served as INOVIO’s President and Chief Executive Officer (CEO) since May 2022. She is responsible for establishing and leading INOVIO’s overall corporate strategy and advancing its DNA medicines platform.

Dr. Shea joined the Company in March 2019 as Chief Operating Officer (COO), serving as a key member of the executive team. She led INOVIO’s manufacturing, commercial, business development, project and alliance management operations.

Dr. Shea has more than 25 years of experience in the life sciences and biotech industries. Prior to joining INOVIO, she was the CEO at Aeras, a not-for-profit organization dedicated to developing new tuberculosis vaccines. Previously, she held leadership roles at Emergent BioSolutions and was also the General Manager and Vice President of The Oxford-Emergent Tuberculosis Consortium. Dr. Shea has dedicated much of her career to developing innovative products to prevent and treat infectious diseases. She has been named as an inventor on more than 20 patents, is an author of numerous scientific publications, has served on multiple advisory boards and previously served on the Board of Trustees for the Sabin Vaccine Institute. Dr. Shea received a BSc Hons in Applied Biology from the University of Bath and a Ph.D. from the National Institute for Medical Research in the UK.